Navigation Links
Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009
Date:3/4/2009

RALEIGH, N.C., March 4 /PRNewswire/ -- Micell Technologies announced today that David E. Kandzari, MD, will present "The Micell Rapid Absorption Polymer DES System" during the Cardiovascular Research Technologies (CRT) meeting in Washington, DC, on March 5, 2009. MiStent(TM), a Drug-Eluting Stent (DES) in pre-clinical studies, utilizes a bioasorbable polymer coating that delivers the potential benefits of the drug during the healing process. The proprietary formulation allows the polymer to be absorbed concurrent with the drug delivery rather than sequentially like other absorbable DES coatings. This allows both the polymer and drug to be eliminated within 90 days and provides the potential for improved patient benefits.

"The Micell DES technology is exciting because it is the first of a new generation of stents being developed to precisely deliver a drug while safely eliminating the polymer faster than any other bioabsorbable coating that is commercially available," said Kandzari. "The unique formulation that allows the polymer to be absorbed at the same time that the drug is being delivered offers the therapeutic benefits of a drug-eluting stent, while quickly transforming itself to the safety profile of a bare metal stent."

Earlier this year, Micell obtained the rights to a CE marked cobalt chromium stent to use as its platform for its proprietary coating. Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell, said, "The pieces are quickly coming together as we demonstrate the advantages of our proprietary formulation and deliver it on a state-of-the-art stent with the lowest strut thickness commercially available. Our scalable drug and polymer coating process serves as a platform for the development of innovative interventional cardiology systems."

Dr. Kandzari is the Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, CA.

About Micell Technologies Inc.

Micell Technologies is a privately-held, development-stage biomedical device company dedicated to developing innovative interventional cardiology systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Its first product in development, MiStent(TM), is a rapid absorbing coated drug-eluting stent with precise control of drug release and pharmacokinetics. Visit us at www.micell.com.

    Contact: Micell Technologies

    Arthur J. Benvenuto, Chairman & CEO
    (919) 313-2104


'/>"/>
SOURCE Micell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):